A surprising finding has emerged from new research on semaglutide, the blockbuster diabetes and weight-loss drug sold as Ozempic and Wegovy: patients taking the medication broke fewer bones than those on competing treatments, even as they lost significantly more weight.
The discovery challenges earlier concerns that rapid weight loss from GLP-1 drugs like semaglutide might weaken bones and increase fracture risk. Researchers analyzed data from over 59,000 patients with type 2 diabetes and found a 15% lower risk of bone fractures among semaglutide users compared with those taking alternative weight-loss medications.
The study, presented at the Endocrine Society's annual conference in Chicago, examined patient records from 2016 through 2023 across U.S. hospitals and medical centers. Researchers led by Dr. Jairo Noreña, formerly of Stanford University Medical Center, tracked fracture rates and body mass index changes in patients receiving either semaglutide or one of three comparison treatments: dulaglutide, phentermine/topiramate, or bupropion/naltrexone.
The numbers tell a clear story. Among 26,324 semaglutide patients, researchers documented 794 fractures. In the comparison group of 33,555 patients on alternative medications, fractures totaled 1,045. That difference persisted even as semaglutide patients achieved larger BMI reductions than their counterparts.
The protective bone effect was unexpected. Prior research had suggested that the rapid weight loss produced by GLP-1 drugs might accelerate bone loss, since weight-bearing activity helps maintain bone density. Slower, gradual weight loss has traditionally been thought to better preserve skeletal health. Semaglutide, however, produces greater weight loss than older anti-obesity medications, yet the data suggests it does not increase fracture risk.
Noreña emphasized that bone fractures carry real human costs. "Bone fractures are painful, expensive and can seriously affect quality of life, especially as people get older," he said. "We hope this study encourages monitoring of bone health in weight-loss programs."
Researchers cautioned that the findings represent an early snapshot. They used a retrospective analysis of existing medical records rather than a prospective study designed specifically to test the bone health hypothesis. Additional research designed to confirm the association and understand the mechanism behind the apparent protective effect will be needed before firm conclusions can be drawn.
The study focused on adults 18 and older with type 2 diabetes who had no previous fracture history and were not taking osteoporosis medications at baseline, narrowing the population to which results directly apply.
Author Jessica Williams: "The irony is striking: the drug that tears through weight loss appears gentler on bones than its rivals, which flips the script on what we thought we knew about rapid weight loss and bone health."
Comments